Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Eli Lilly and Company Limited
Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL
Telephone: +44 (0)1256 315 000
Fax: +44 (0)1256 775 858
WWW: http://www.lilly.co.uk
Medical Information e-mail: ukmedinfo@lilly.com
Medical Information Fax: +44 (0)1256 775 569

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 30/11/2011
PIL Strattera 10mg, 18mg, 25mg, 40mg, 60mg or 80mg hard capsules.

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 30/11/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 09/11/2011 and displayed until 30/11/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
Updated on 01/12/2009 and displayed until 09/11/2011
Reasons for adding or updating:
  • Change of active ingredient
  • Change to date of revision
Updated on 09/01/2009 and displayed until 01/12/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Introduction of new strength
Updated on 30/04/2008 and displayed until 09/01/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 25/02/2008 and displayed until 30/04/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change to Marketing Authorisation Holder
Updated on 29/03/2007 and displayed until 25/02/2008
Reasons for adding or updating:
  • Change to how to administer the medicine
  • Change to storage instructions
  • Change to date of revision
Updated on 28/02/2007 and displayed until 29/03/2007
Reasons for adding or updating:
  • Change to how to administer the medicine
  • Change to storage instructions
  • Change to date of revision
Updated on 11/12/2006 and displayed until 28/02/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change to date of revision
Updated on 02/05/2006 and displayed until 11/12/2006
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to drug interactions
  • Change to side-effects
  • Change to date of revision
Updated on 27/10/2005 and displayed until 02/05/2006
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 16/02/2005 and displayed until 27/10/2005
Reasons for adding or updating:
  • PIL Retired pending re-submission
  • Change to side-effects
  • Change to date of revision
Updated on 16/06/2004 and displayed until 16/02/2005
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  atomoxetine hydrochloride